Apellis Pharmaceuticals, Inc.
NASDAQ: APLS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cedric Francois
- Employees
- 705
- Headquarters
- Waltham, United States
- IPO year
- 2017
- Market cap
- $5.3B
- Website
- https://www.apellis.com
Loading APLS…
Loading profile data…Frequently asked questions about APLS
What does Apellis Pharmaceuticals, Inc. (APLS) do?
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacop...
Where does APLS trade?
Apellis Pharmaceuticals, Inc. (APLS) trades on the NASDAQ Global Select.
What sector is APLS in?
Apellis Pharmaceuticals, Inc. (APLS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Apellis Pharmaceuticals, Inc.?
Cedric Francois is the chief executive officer of Apellis Pharmaceuticals, Inc. (APLS).
Where is Apellis Pharmaceuticals, Inc. headquartered?
Apellis Pharmaceuticals, Inc. is headquartered in United States.
Does APLS pay a dividend?
Apellis Pharmaceuticals, Inc. (APLS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did APLS go public?
Apellis Pharmaceuticals, Inc. (APLS) completed its initial public offering in 2017.